2Dieye A, Obami-Ttou V, Barry MF, et al. Association between Class IHLA allles and HBs antigen carrier status among blood donors in Senegal. Dakar Med, 1999,44(2) : 166-170.
3Barth H, Klein R, Berg PA, et al. Tnduction of T helper cell type 1 response and elimination of HBeAg during treatment with TL-12 in a patient with therapy-refractory chronic hepatitis B. HepatogastroenteroLogY, 2001,48 (38) : 553-555.
4Merkle H, Deutschle T, Gastrock-Balitsch T, et al. H-2(d) mice born to and reared by HBeAg-transgenic mothers do not develop T cell tolerance toward the hepatitis B virus core gene products. Virology, 2000, 273 ( 1 ) :149-159.
5Khakoo SI, Ling R, Scott l, et al. Cytotoxic T lymphocyte resDonses and CTL epitope escape mutation in HBsAg, anti-HBe positi. ve individuals.Gut, 2000,47(1) : 137-143.
6Zavaglia C, Severini R, Tinelli C, et al. A randomized, controlled study of thymosin-alphal therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci, 2000, 45(4) :690-696.
7Krastev Z, Jelev D, Antonov K, et al. Chronic HBV infection. Tmmunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients-a pilot study. Hepatogastroenterology, 1999, 46(30) : 3184-3188.
8Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of precore mutant chronic hepatitis B. J Viral Hepat, 2001, 8(5) :311-321.
9Dong J, Cheng J, Wang Q, et al. The study on heterogeneity of hepatitis B virus DNA. Zhonghua Yi Xue Za Zhi, 2002, 82(2) :81-85.
10Scaglioni PP, Melegari M, Wands JR. Posttranscrlptional regulation of hepatitis B virus repl' ication by the precore protein. J Virol, 1997,71(1) :345-353.
